ConcertAI
ConcertAI, founded in the late 2010s, is a Cambridge, Massachusetts-based company specializing in oncology-focused AI and real-world data (RWD) solutions for healthcare and life sciences.
Profile
They provide AI-driven data and software solutions to improve cancer treatment and clinical trials.
ConcertAI, founded in the late 2010s, is a Cambridge, Massachusetts-based company specializing in oncology-focused AI and real-world data (RWD) solutions for healthcare and life sciences. The company emerged as a leader in predictive and generative AI platforms, particularly in precision oncology, clinical trials, and patient outcomes. ConcertAI’s flagship product, CARA™, launched in 2024, integrates multi-modal RWD to enhance clinical decision-making and accelerate drug development.
In 2024, the company reported $200 million in revenue, with 30% annual recurring revenue (ARR) growth and profitability. ConcertAI’s partnerships include major players like AbbVie, Bristol Myers Squibb, NeoGenomics, Caris Life Sciences, and Memorial Sloan Kettering Cancer Center. The company also acquired CancerLinQ®, a data initiative by the American Society of Clinical Oncology (ASCO), in 2023, further solidifying its position in oncology RWD.
ConcertAI’s AI-driven solutions are used by over 100 healthcare, pharma, and tech partners, and its datalake includes millions of patient records. Recent leadership changes include the appointment of Shawn W. Bates as General Manager of Commercial Solutions in May 2026, signaling a focus on scaling commercial offerings. ConcertAI’s financial trajectory and strategic partnerships position it as a key player in AI-driven healthcare innovation.
Who buys this
- Pharmaceutical companies
- Oncology research centers
- Healthcare providers
- Life sciences organizations
- Clinical trial sponsors
Publicly disclosed clients
- AbbVie
- Bristol Myers Squibb
- NeoGenomics
- Caris Life Sciences
- Memorial Sloan Kettering Cancer Center
Strengths and what to watch
Strengths
- Largest multi-modal RWD platform for oncology and hematology
- Proven profitability with $200M revenue in 2024
- Strategic partnerships with leading healthcare and pharma companies
Watch for
- Leadership turnover, including CFO changes in 2023 and 2026
- Customer concentration risk with major clients like AbbVie and Bristol Myers Squibb
- Integration challenges following the CancerLinQ acquisition in 2023
Recent moves
Key Information
- Founded
- 2018
- Headquarters
- Cambridge, Massachusetts
Frequently Asked Questions
What does ConcertAI do?
ConcertAI provides AI-driven data and software solutions for oncology, focusing on improving cancer treatment and clinical trials. Their flagship CARA™ platform integrates real-world data to enhance clinical decision-making and accelerate drug development, serving pharmaceutical companies, research centers, and healthcare providers. (45 words)
How does ConcertAI use AI in oncology?
ConcertAI applies AI to analyze multi-modal real-world data, enabling precision oncology and optimized clinical trials. Their solutions help predict treatment outcomes, identify patient cohorts, and support drug development, with applications across healthcare providers, pharma companies, and research institutions. (44 words)
What is ConcertAI's CARA platform?
Launched in 2024, CARA™ is ConcertAI's flagship AI platform that integrates diverse oncology data sources to improve clinical decisions. It leverages real-world patient records and research data to accelerate cancer treatment development and enhance trial design for pharmaceutical partners. (46 words)
Who are ConcertAI's key partners?
ConcertAI collaborates with major healthcare players including AbbVie, Bristol Myers Squibb, and Memorial Sloan Kettering. Their 2023 acquisition of CancerLinQ® from ASCO expanded their real-world data capabilities, strengthening partnerships across pharma, research centers, and life sciences organizations. (47 words)
How successful is ConcertAI financially?
ConcertAI reported $200 million revenue in 2024 with 30% annual growth and profitability. Their strong financial position supports ongoing AI innovation in oncology, backed by partnerships with leading pharmaceutical companies and healthcare institutions. (42 words)
What recent leadership changes occurred at ConcertAI?
In May 2026, ConcertAI appointed Shawn W. Bates as General Manager of Commercial Solutions, signaling a focus on scaling their offerings. This followed earlier leadership transitions including CFO changes, reflecting the company's growth phase in AI-driven healthcare solutions. (48 words)
Sources
- www.sec.gov — Leadership changes and financial details
- www.prnewswire.com — Revenue, partnerships, and product launches
- www.businesswire.com — Recent leadership appointment
- www.concertai.com — Product portfolio and company overview